Imetelstat: a first-in-class telomerase inhibitor
A unique molecule targeting a hallmark of cancer
2021 Virtual Annual Meeting of Stockholders
Event details are available
Stockholder Letter
from our CEO
Together we can make a difference in patients’ lives
Partnering is a key to our success
A visionary history
Creating a legacy of bold innovation